ACE2 and COVID-19: The discovery of ACE2 almost two decades ago as the principal component of the non-classical arm of the renin–angiotensin system (RAS) has opened new avenues for effective therapies in cardiovascular diseases (CVDs) and COVID-19 [38,39,40,41,42].